AlzeCure Pharma AB announced the appointment of Märta Segerdahl, MD, PhD, Associate professor, as Chief Medical Officer (CMO) and member of executive management team.

She succeeds An van Es-Johansson, MD, currently CMO and Head of Development, and previously member of the Board, who will continue working as an advisor. Märta Segerdahl will lead the clinical development organization, and she will have the medical responsibility for AlzeCures’s drug development candidates. The pharmaceutical company, based in Huddinge, develops drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain. Segerdahl brings more than 15 years of industry experience from both big pharma and small biotech. Recent positions include CMO at Asarina Pharma ApS, Chief Medical Specialist at Lundbeck A/S, Senior Medical Director Medical Intelligence at Grünenthal GmbH, and Global Medical Science Director Emerging Cognition at AstraZeneca.